

Klemens Fheodoroff

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5510342/publications.pdf>

Version: 2024-02-01

54
papers

572
citations

759055

12
h-index

677027

22
g-index

69
all docs

69
docs citations

69
times ranked

492
citing authors

#	ARTICLE	IF	CITATIONS
1	Results from the Upper Limb International Spasticity Study-II (ULIS-II): a large, international, prospective cohort study investigating practice and goal attainment following treatment with botulinum toxin A in real-life clinical management. <i>BMJ Open</i> , 2013, 3, e002771.	0.8	64
2	An international survey of patients living with spasticity. <i>Disability and Rehabilitation</i> , 2017, 39, 1428-1434.	0.9	44
3	Diagnosis and treatment of neurogenic dysphagia – S1 guideline of the German Society of Neurology. <i>Neurological Research and Practice</i> , 2021, 3, 23.	1.0	38
4	Upper limb international spasticity study: rationale and protocol for a large, international, multicentre prospective cohort study investigating management and goal attainment following treatment with botulinum toxin A in real-life clinical practice. <i>BMJ Open</i> , 2013, 3, e002230.	0.8	37
5	Consensus guidelines for botulinum toxin therapy: general algorithms and dosing tables for dystonia and spasticity. <i>Journal of Neural Transmission</i> , 2021, 128, 321-335.	1.4	37
6	Common goal areas in the treatment of upper limb spasticity: a multicentre analysis. <i>Clinical Rehabilitation</i> , 2016, 30, 617-622.	1.0	34
7	Effectiveness of Integration and Re-Integration into Work Strategies for Persons with Chronic Conditions: A Systematic Review of European Strategies. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 552.	1.2	28
8	Impact of integrated upper limb spasticity management including botulinum toxin A on patient-centred goal attainment: rationale and protocol for an international prospective, longitudinal cohort study (ULIS-III). <i>BMJ Open</i> , 2016, 6, e011157.	0.8	27
9	Consensus statement: Botulinum toxin in myofacial pain. <i>Journal of Neurology</i> , 2004, 251, i36-i38.	1.8	25
10	Mapping European Welfare Models: State of the Art of Strategies for Professional Integration and Reintegration of Persons with Chronic Diseases. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 781.	1.2	21
11	Effectiveness of AbobotulinumtoxinA in Post-stroke Upper Limb Spasticity in Relation to Timing of Treatment. <i>Frontiers in Neurology</i> , 2020, 11, 104.	1.1	19
12	Factors Influencing Goal Attainment in Patients with Post-Stroke Upper Limb Spasticity Following Treatment with Botulinum Toxin A in Real-Life Clinical Practice: Sub-Analyses from the Upper Limb International Spasticity (ULIS)-II Study. <i>Toxins</i> , 2015, 7, 1192-1205.	1.5	17
13	Longitudinal goal attainment with integrated upper limb spasticity management including repeat injections of botulinum toxin A: Findings from the prospective, observational Upper Limb International Spasticity (ULIS-III) cohort study. <i>Journal of Rehabilitation Medicine</i> , 2021, 53, jrm00157.	0.8	17
14	A synthesis and appraisal of clinical practice guidelines, consensus statements and Cochrane systematic reviews for the management of focal spasticity in adults and children. <i>Disability and Rehabilitation</i> , 2020, , 1-11.	0.9	15
15	Experienced complaints, activity limitations and loss of motor capacities in patients with pure hereditary spastic paraplegia: a web-based survey in the Netherlands. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 64.	1.2	13
16	Spasticity or reversible muscle hypertonia?. <i>Journal of Rehabilitation Medicine</i> , 2011, 43, 556-557.	0.8	11
17	Policy Guidelines for Effective Inclusion and Reintegration of People with Chronic Diseases in the Workplace: National and European Perspectives. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 493.	1.2	11
18	Quality of life in subjects with upper- and lower-limb spasticity treated with incobotulinumtoxinA. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 51.	1.0	11

#	ARTICLE	IF	CITATIONS
19	Assessing the effectiveness of upper-limb spasticity management using a structured approach to goal-setting and outcome measurement: First cycle results from the ULIS-III Study. <i>Journal of Rehabilitation Medicine</i> , 2021, 53, jrm00133.	0.8	11
20	How Can We Improve Current Practice in Spastic Paresis?. <i>European Neurological Review</i> , 2016, 11, 79.	0.5	11
21	Furthering the Evidence of the Effectiveness of Employment Strategies for People with Mental Disorders in Europe: A Systematic Review. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 838.	1.2	9
22	Time to retreatment with botulinum toxin A in upper limb spasticity management: Upper limb international spasticity (ULIS)-III study interim analysis. <i>Toxicon</i> , 2018, 156, S110-S111.	0.8	7
23	Ixcellence Network ^{1/2} : an international educational network to improve current practice in the management of cervical dystonia or spastic paresis by botulinum toxin injection. <i>Functional Neurology</i> , 2017, 32, 103.	1.3	7
24	ULIS (Upper Limb International Spasticity), a 10-year Odyssey. <i>The Journal of the International Society of Physical and Rehabilitation Medicine</i> , 2019, 2, 138-150.	0.1	6
25	Phenotype and Ctg-Repeat Size in Myotonic Dystrophy: A Study of 26 Patients and 55 Relatives. <i>Journal of Neurogenetics</i> , 1999, 13, 181-190.	0.6	5
26	Management of Spastic Paresis and Cervical Dystonia: Access to Therapeutic Innovations Through an International Program of Practical Courses. <i>Clinical Therapeutics</i> , 2019, 41, 2321-2330.e4.	1.1	5
27	Goal analysis in patients with limb spasticity treated with incobotulinumtoxinA in the TOWER study. <i>Disability and Rehabilitation</i> , 2020, , 1-7.	0.9	5
28	Validity and Reliability of the Spasticity-Associated Arm Pain Scale. <i>Journal of Pain Management & Medicine</i> , 2017, 03, .	0.2	5
29	Identifying the Employment Needs of People With Chronic Health Conditions in Europe. <i>Journal of Occupational and Environmental Medicine</i> , 2018, 60, e618-e624.	0.9	4
30	Spastic Paresis and Rehabilitation – The Patient Journey. <i>European Neurological Review</i> , 2016, 11, 87.	0.5	4
31	Integrated upper limb spasticity management including botulinum toxin A (BoNT-A) on patient-centred goal attainment: Methodology for ULIS-III and initial goal-setting data. <i>Toxicon</i> , 2016, 123, S81.	0.8	2
32	Do randomised controlled trials evaluating functional outcomes following botulinum neurotoxin-A align with focal spasticity guidelines? A systematic review. <i>Disability and Rehabilitation</i> , 2022, 44, 8515-8523.	0.9	2
33	Efficacy of Four-Channel Functional Electrical Stimulation on Moderate Arm Paresis in Subacute Stroke Patients – Results from a Randomized Controlled Trial. <i>Healthcare (Switzerland)</i> , 2022, 10, 704.	1.0	2
34	Economic outcomes in real-world use of botulinum toxin-A products for adult patients with upper limb spasticity: A UK perspective. <i>Toxicon</i> , 2021, 190, S73.	0.8	1
35	Real-life data on the time to retreatment with botulinum toxin type A in upper limb spasticity management. <i>Toxicon</i> , 2021, 190, S34.	0.8	1
36	The spasticity-related quality of life 6-dimensions instrument in upper-limb spasticity: Development and responsiveness. <i>Journal of Rehabilitation Medicine</i> , 2021, , .	0.8	1

#	ARTICLE	IF	CITATIONS
37	The spasticity-related quality of life 6-dimensions instrument in upper-limb spasticity: A first psychometric evaluation. Journal of Rehabilitation Medicine, 2021, , .	0.8	1
38	Outcomes Related to Passive Function in a Cohort of Patients Treated With Botulinum Toxin A (Bont-A) for Post-Stroke Upper Limb Spasticity - ULIS II Study. PM and R, 2013, 5, S235-S235.	0.9	0
39	Outcomes Related to Pain in a Cohort of Patients Treated with Botulinum Toxin A (BoNT-A) for Post-Stroke Upper Limb Spasticity - ULIS II Study. PM and R, 2013, 5, S243-S243.	0.9	0
40	Outcomes Related to Active Function in a Cohort of Patients Treated With Botulinum Toxin A (Bont-A) for Post-Stroke Upper Limb Spasticity - ULIS II Study. PM and R, 2013, 5, S240-S240.	0.9	0
41	Upper Limb International Spasticity Study-II (ULIS-II): Results of a Large, International, Prospective Cohort Study Investigating Practice and Goal Attainment Following Treatment With Botulinum Toxin A in Real-Life Clinical Management. PM and R, 2013, 5, S238-S239.	0.9	0
42	110. Factors influencing goal attainment in patients with poststroke upper limb spasticity following treatment with botulinum neurotoxin A in real-life clinical practice: subanalyses from the Upper Limb International Spasticity (ULIS)-II Study. Toxicon, 2015, 93, S33-S34.	0.8	0
43	Correlations between spasticity, goal attainment, and global assessment of benefits in patients with upper limb spasticity treated with botulinum toxin A. Toxicon, 2016, 123, S20-S21.	0.8	0
44	An innovative international educational network to improve physicians' current management practices for patients with cervical dystonia and spasticity. Toxicon, 2016, 123, S41.	0.8	0
45	A comparison of goal selection and achievement between botulinum toxin A (BoNT-A) naÃve and non-naÃve patients in the upper limb international spasticity (ULIS)-II study. Toxicon, 2016, 123, S59-S60.	0.8	0
46	Poster 373â¬ Integrated Upper Limb Spasticity Management Including Botulinum Toxin A (BoNTâ¬) on Patientâ¬Centered Goal Attainment: Methodology for ULISâ¬III and Initial Goalâ¬Setting Data. PM and R, 2016, 8, S331.	0.9	0
47	Poster 313 Relationship Between AbobotulinumtoxinA Injections into Shoulder Muscles and Patient Centred Primary Goal Selection and Achievement: Sub-Analyses from the Upper Limb International Spasticity (ULIS)-II Study. PM and R, 2016, 8, S262.	0.9	0
48	Poster 57: Time to Retreatment with Botulinum Toxin A in Upper Limb Spasticity Management: Initial Data from the Upper Limb International Spasticity (ULIS)â¬III Study. PM and R, 2017, 9, S155.	0.9	0
49	Poster 52: Botulinum Toxin A in Upper Limb Spasticity Management: Baseline Data from the Upper Limb International Spasticity (ULIS)-III Study. PM and R, 2018, 10, S25-S25.	0.9	0
50	Poster 55: Relief of Spasticity-Related Pain with Botulinum Neurotoxin-A (BoNT-A) in Real Life Practice. Post-Hoc Analysis from a Large International Cohort Series. PM and R, 2018, 10, S25-S26.	0.9	0
51	The spasticity-related quality of life 6-dimensions tool (SQoL-6D) in upper limb spasticity: A first psychometric evaluation. Toxicon, 2021, 190, S73-S74.	0.8	0
52	Clinical Trial Adherence to Focal Muscle Spasticity Guidelines: A Systematic Review. Archives of Physical Medicine and Rehabilitation, 2021, 102, e112.	0.5	0
53	ICF basierte Zielsetzung in der Funktionellen Elektrostimulation. , 2021, , 49-58.		0
54	Kombinationstherapien mit der Funktionellen Elektrostimulation. , 2021, , 181-199.		0